These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9734667)

  • 1. The use of amphotericin B lipid complex in 15 patients with presumed or proven fungal infection.
    Allsup D; Chu P
    Br J Haematol; 1998 Sep; 102(4):1109-10. PubMed ID: 9734667
    [No Abstract]   [Full Text] [Related]  

  • 2. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections.
    Blyth CC; Hale K; Palasanthiran P; O'Brien T; Bennett MH
    Cochrane Database Syst Rev; 2010 Feb; 2010(2):CD006343. PubMed ID: 20166083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK.
    Flynn TN; Kelsey SM; Hazel DL; Guest JF
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):543-50. PubMed ID: 10662479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid preparations of amphotericin for the treatment of fungal infections.
    Mehta J
    Br J Haematol; 1999 Jun; 105(3):845-9; author reply 849-50. PubMed ID: 10354162
    [No Abstract]   [Full Text] [Related]  

  • 5. [Amphotericin B: the end of an era].
    Oude Lashof AM; Kullberg BJ
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1665-8. PubMed ID: 15453116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal amphotericin B for the treatment of severe fungal infection.
    Michaud D
    Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Amphotericin B: the end of an era].
    Rommes JH; Spronk PE; Saene HK
    Ned Tijdschr Geneeskd; 2005 Jan; 149(2):106; author reply 106-7. PubMed ID: 15688845
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B.
    Bellmann R; Cleary JD; Sterba J
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-8. PubMed ID: 19537331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study of amphotericin B in the treatment of invasive fungal infection in 111 hematological disorder patients with neutrocytopenia].
    Tong HY; Zhang FJ; Xiao F; Qian WB; Meng HT; Mai WY; Tong Y; Mao LP; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):472-5. PubMed ID: 19035181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal agents used for deep-seated mycotic infections.
    Hermans PE; Keys TF
    Mayo Clin Proc; 1983 Apr; 58(4):223-31. PubMed ID: 6339832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses.
    Wingard JR
    Bone Marrow Transplant; 1997 Feb; 19(4):343-7. PubMed ID: 9051244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid amphotericin B formulations as comparators in clinical trials.
    Powers JH; Albrecht R
    Clin Infect Dis; 2004 Jan; 38(2):305-6; author reply 306-7. PubMed ID: 14699471
    [No Abstract]   [Full Text] [Related]  

  • 13. The use of liposomal amphotericin B in the treatment of neutropenia-associated fungal infections: efficacy and cost-effectiveness.
    Newland AC
    Br J Haematol; 1999 Feb; 104(2):425-6. PubMed ID: 10050732
    [No Abstract]   [Full Text] [Related]  

  • 14. [New aspects in treatment of systemic mycoses].
    Presterl E; Graninger W
    Wien Klin Wochenschr; 1998 Nov; 110(21):740-50. PubMed ID: 9871965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of liposomal amphotericin B in critically ill patients: a retrospective, multicenter, clinical study.
    Alvarez-Lerma F; Mariscal F; Quintana E; Rialp G; Diaz-Reganon J; Perez MJ; Alvarez-Sanchez B; Ausin Aoiz I;
    J Chemother; 2009 Jun; 21(3):330-7. PubMed ID: 19567355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
    Brogden RN; Goa KL; Coukell AJ
    Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amphotericin B: is a lipid-formulation gold standard feasible?
    Spellberg B; Witt MD; Beck CK
    Clin Infect Dis; 2004 Jan; 38(2):304-5; author reply 306-7. PubMed ID: 14699470
    [No Abstract]   [Full Text] [Related]  

  • 18. Liposomal amphotericin B (Ambisome) is safe and effective in the treatment of invasive mycosis in organ transplant patients.
    Merhav H; Nakache R; Houri I; Orni-Wasserlauf R
    Transplant Proc; 2001 Sep; 33(6):2937-8. PubMed ID: 11543798
    [No Abstract]   [Full Text] [Related]  

  • 19. Controlled trials of amphotericin B lipid complex and other lipid-associated formulations.
    Winston DJ; Schiller GJ
    Clin Infect Dis; 2000 Jan; 30(1):236-7. PubMed ID: 10619780
    [No Abstract]   [Full Text] [Related]  

  • 20. Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry-supported patient registry.
    Pappas PG
    Clin Infect Dis; 2005 May; 40 Suppl 6():S379-83. PubMed ID: 15809923
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.